Virpax Pharmaceuticals Inc (VRPX)

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Virpax Pharmaceuticals Announces Reverse Stock Split

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain...

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain...

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain...

Form 8-K - Current report

Form 8-K - Current report

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain...

Form 8-K - Current report

Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering

NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service...

Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and...